Foghorn Therapeutics Inc Asset Resilience Ratio
Foghorn Therapeutics Inc asset resilience ratio. Foghorn Therapeutics Inc (FHTX) has an Asset Resilience Ratio of 48.92% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Foghorn Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Foghorn Therapeutics Inc (2020–2025)
Asset resilience ratio of Foghorn Therapeutics Inc from 2020 to 2025. This chart shows how Foghorn Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Foghorn Therapeutics Inc (FHTX) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Foghorn Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see FHTX asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $99.50 Million | 48.92% |
| Total Liquid Assets | $99.50 Million | 48.92% |
Asset Resilience Insights
- Very High Liquidity: Foghorn Therapeutics Inc maintains exceptional liquid asset reserves at 48.92% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Foghorn Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Foghorn Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Foghorn Therapeutics Inc Asset Resilience Ratio by Year (2020–2025)
Foghorn Therapeutics Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Foghorn Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 39.38% | $78.02 Million | $198.10 Million | -26.92pp |
| 2024-12-31 | 66.30% | $188.29 Million | $283.98 Million | +12.54pp |
| 2023-12-31 | 53.76% | $153.72 Million | $285.92 Million | -18.75pp |
| 2022-12-31 | 72.51% | $293.58 Million | $404.88 Million | +62.28pp |
| 2021-12-31 | 10.23% | $53.15 Million | $519.77 Million | -26.15pp |
| 2020-12-31 | 36.38% | $92.97 Million | $255.59 Million | -- |
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mu… Read more